amount of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4 cm-1.

116. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 114.

117. A pharmaceutical composition comprising a compound according to claim 114 and a pharmaceutically acceptable carrier.

118. A composition according to claim 114 in which the carrier comprises a binder.

119. A composition according to claim 114 in which the carrier comprises a colouring agent.

120. A composition according to claim 114 in which the carrier comprises a flavouring agent.

121. A composition according to claim 114 in which the carrier comprises a preservative.

122. A composition according to claim 114 adapted for oral administration.

123. A composition according to claim 122 which is a tablet or capsule.

124. A composition according to claim 123 which is a modified oval shaped tablet.

125. A composition according to claim 114 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

126. A pharmaceutical composition adapted for oral administration comprising per unit dose 10, 12.5, 15, 20, 25, 30 or 40 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4 cm^{-1}, and a pharmaceutically acceptable carrier.

127. A pharmaceutical composition adapted for oral administration comprising per unit dose 10 mg, calculated on a free base basis, of paroxetine methanesulfonate having the

following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

128. A pharmaceutical composition adapted for oral administration comprising per unit dose 20 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

129. A pharmaceutical composition adapted for oral administration comprising per unit dose 30 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

130. A pharmaceutical composition adapted for oral administration comprising per unit dose 40 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

131. A pharmaceutical composition adapted for oral administration comprising per unit dose 12.5 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

132. A pharmaceutical composition adapted for oral administration comprising per unit dose 15 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

133. A pharmaceutical composition adapted for oral administration comprising per unit dose 25 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier.

134. A pharmaceutical composition adapted for oral administration comprising per unit dose 50 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 ± 4cm^{-1}, and a pharmaceutically acceptable carrier

135. Paroxetine methanesulfonate having *inter alia* the following characteristic IR peaks: 1603, 1513, 1194, 1045, 946, 830, 776, 601, 554 and 539 cm-1; and/or the following characteristic XRD peaks: 8.3, 10.5, 15.6, 16.3, 17.7, 18.2, 19.8, 20.4, 21.5, 22.0, 22.4, 23.8, 24.4, 25.0, 25.3, 25.8, 26.6, 30.0, 30.2 and 31.6.

136. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate in crystalline form having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554 and 539 cm-1.

137. A method of treating or preventing a disease state selected from: depression, panic disorder, pre-menstrual syndrome, anxiety, obsessive compulsive disorder, social phobia and adolescent depression, which comprises administering an effective or prophylactic amount of paroxetine methanesulfonate, as described in claim 135.

138. A pharmaceutical composition comprising a compound according to claim 135 and a pharmaceutically acceptable carrier.

139. A composition according to claim 135 in which the carrier comprises a binder.

140. A composition according to claim 135 in which the carrier comprises a colouring agent.

141. A composition according to claim 135 in which the carrier comprises a flavouring agent.

142. A composition according to claim 135 in which the carrier comprises a preservative.

143. A composition according to claim 135 adapted for oral administration.

144. A composition according to claim 143 which is a tablet or capsule.

145. A composition according to claim 144 which is a modified oval shaped tablet.

146. A composition according to claim 126 comprising 1 to 200mg of active ingredient, calculated on a free base basis.

147. A pharmaceutical composition adapted for oral administration comprising per unit dose 10 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

148. A pharmaceutical composition adapted for oral administration comprising per unit dose 20 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

149. A pharmaceutical composition adapted for oral administration comprising per unit dose 30 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

150. A pharmaceutical composition adapted for oral administration comprising per unit dose 40 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

151. A pharmaceutical composition adapted for oral administration comprising per unit dose 12.5 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

152. A pharmaceutical composition adapted for oral administration comprising per unit dose 15 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

153. A pharmaceutical composition adapted for oral administration comprising per unit dose 25 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.

154. A pharmaceutical composition adapted for oral administration comprising per unit dose 50 mg, calculated on a free base basis, of paroxetine methanesulfonate having the following characteristic IR peaks: 1603, 1194, 1045, 946, 830, 601, 554, and 539 cm^{-1}, and a pharmaceutically acceptable carrier.